ASTRO 2025: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial UroTodayRadiopharmaceutical added to stereotactic radiation can delay prostate cancer progression Medical XpressNew therapy delays progression of recurrent prostate cancer Medical Xpress